Compass Therapeutics Inc Ordinary Shares CMPX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Compass Therapeutics to Participate in Upcoming Investor Events
-
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
-
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
-
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
-
Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment
Trading Information
- Previous Close Price
- $1.73
- Day Range
- $1.67–1.82
- 52-Week Range
- $0.77–2.34
- Bid/Ask
- $1.81 / $1.84
- Market Cap
- $249.04 Mil
- Volume/Avg
- 337,909 / 445,360
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 281.76
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 32
Comparables
Valuation
|
Metric
|
CMPX
|
JANX
|
TNGX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.70 | 3.70 | 3.17 |
Price/Sales | 281.76 | 150.99 | 18.09 |
Price/Cash Flow | — | — | — |
Price/Earnings
CMPX
JANX
TNGX
Financial Strength
|
Metric
|
CMPX
|
JANX
|
TNGX
|
|---|---|---|---|
Quick Ratio | 15.38 | 57.02 | 7.34 |
Current Ratio | 16.15 | 57.34 | 7.49 |
Interest Coverage | — | — | — |
Quick Ratio
CMPX
JANX
TNGX
Profitability
|
Metric
|
CMPX
|
JANX
|
TNGX
|
|---|---|---|---|
Return on Assets (Normalized) | −24.24% | −4.75% | −24.41% |
Return on Equity (Normalized) | −25.57% | −5.12% | −38.87% |
Return on Invested Capital (Normalized) | −30.29% | −9.37% | −35.94% |
Return on Assets
CMPX
JANX
TNGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lxjvyrmmj | Nvdrd | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yhgyqjhv | Swnqqqw | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hxmdktm | Hnvmtz | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Clsrxksxv | Qgcjtc | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Htjbxjhpd | Jtxj | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Dwwvddrn | Qtljf | $28.0 Bil | |||
| Moderna Inc
MRNA
| Zgpmxgdw | Vsshx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Hqlbmfb | Gjql | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xzmhmnqc | Bfprgp | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Lqmqfrpcqt | Gdhmnzs | $12.6 Bil |
United States